CSCIF on OTC
COSCIENS Biopharma Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with UNITED GUARDIAN INC, cbdMD, Inc. or DSwiss Inc, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
35.3%Gross margin2
-142.5%Operating margin2
-138.1%Net margin2
-21.8%Revenue growth, 20252
-$9.2MFree cash flow2
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Active ingredients [member] brought in 94% of the revenue COSCIENS Biopharma Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Active ingredients [member] | $7.1M | $8.5M | $7.0M |
| Biopharmaceutical | $1.1M | $461.0K |
Business segments
Active ingredient [member] brought in 94% of the revenue COSCIENS Biopharma Inc. broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2023 | 2024 | 2025 |
|---|---|---|---|
| Active ingredient [member] | $7.1M | $8.5M | $7.0M |
| Biopharmaceutical | $1.1M | $461.0K |
Regions
United states [member] brought in 61% of the revenue COSCIENS Biopharma Inc. broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United states [member] | $3.4M | $6.7M | $4.6M |
| Germany [member] | $3.6M | $1.4M | $2.4M |
| United kingdom [member] | $976.0K | $457.0K | |
| Other | $164.0K | $260.0K | $59.0K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Other costs100¢$7.5M
Out of $7.5M in revenue.2 The company lost money this year.
Financial statements
No quarterly figures reported.
Every line of the income statement in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenues (note 6) | $7.5M | $9.6M | $7.1M |
| Cost of sales | -$4.9M | -$4.9M | -$4.2M |
| Gross profit | $2.6M | $4.7M | $2.9M |
| Research and development | -$3.0M | -$8.3M | -$2.0M |
| Selling, general and administrative | -$10.1M | -$10.4M | -$5.5M |
| Impairment of property and equipment (note 12) | -$240.0K | -$1.1M | |
| Write-down of inventory (note 9) | -$76.0K | ||
| Impairment of intangible assets (note 13) | -$3.2M | ||
| Total expenses | -$13.3M | -$23.0M | -$7.6M |
| Loss from operations | -$10.7M | -$18.3M | -$4.6M |
| Foreign exchange gain (loss) | -$196.0K | $48.0K | -$24.0K |
| Finance costs | -$168.0K | -$129.0K | -$136.0K |
| Interest income | $283.0K | $441.0K | $59.0K |
| Other income | $35.0K | $98.0K | $360.0K |
| Change in fair value of warrant and DSU liabilities | $379.0K | $2.6M | |
| Other income | $333.0K | $3.1M | $259.0K |
| Loss before income taxes | -$10.3M | -$15.2M | -$4.4M |
| Income tax recovery (expense) (note 22) | -$10.0K | -$84.0K | $885.0K |
| Net loss | -$10.4M | -$15.3M | -$3.5M |
| Foreign currency translation adjustments | -$961.0K | -$771.0K | $492.0K |
| Actuarial gain (loss) on defined benefit plans (note 16) | $2.0M | -$1.2M | |
| Comprehensive loss | -$9.4M | -$17.2M | -$3.0M |
| Loss per share - Basic | -$3.27 | -$5.93 | -$1.89 |
| Loss per share - Diluted | -$3.27 | -$5.93 | -$1.89 |
No quarterly figures reported.
Every line of the balance sheet in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents (note 7) | $7.3M | $16.4M | $6.7M |
| Trade and other receivables (note 8) | $1.3M | $2.4M | |
| Inventories (note 9) | $1.3M | $2.7M | |
| Income taxes receivable | $114.0K | ||
| Prepaid expenses and other assets (note 10) | $1.6M | $2.4M | |
| Assets held for sale (note 11) | $37.0K | ||
| Total current assets | $11.5M | $24.0M | |
| Restricted cash and cash equivalents (note 7) | $125.0K | $123.0K | |
| Property and equipment (note 12) | $9.8M | $11.0M | |
| Total non-current assets | $9.9M | $11.1M | |
| Total assets | $21.4M | $35.1M | |
| Payables and accrued liabilities (note 14) | $1.9M | $4.7M | |
| Provisions | $269.0K | $385.0K | |
| Income taxes payable | $122.0K | $105.0K | |
| Current portion of deferred revenues (note 6) | $120.0K | ||
| Current portion of lease liabilities (note 15) | $215.0K | $271.0K | |
| Warrant liability (note 17) | $1.1M | $1.6M | |
| DSU liability (note 18) | $48.0K | ||
| Total current liabilities | $3.6M | $7.2M | |
| Deferred revenues (note 6) | $1.1M | $914.0K | |
| Lease liabilities (note 15) | $1.9M | $2.0M | |
| Employee future benefits (note 16) | $11.0M | $11.7M | |
| Total non-current liabilities | $14.0M | $14.7M | |
| Total liabilities | $17.6M | $21.9M | |
| Share capital (note 19) | $22.6M | $22.5M | |
| Contributed surplus (note 19) | $4.2M | $4.3M | |
| Retained earnings (accumulated deficit) | -$20.5M | -$12.1M | |
| Accumulated other comprehensive loss | -$2.4M | -$1.5M | |
| Total shareholders equity | $3.8M | $13.2M | $21.0M |
| Total liabilities and shareholders equity | $21.4M | $35.1M |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$10.4M | -$15.3M | -$3.5M |
| Depreciation and amortization | $1.2M | $1.6M | $1.4M |
| Share-based compensation costs | -$12.0K | $464.0K | $192.0K |
| Impairment of intangible assets (note 13) | $3.2M | ||
| Impairment of property and equipment (note 12) | $240.0K | $1.1M | |
| Write-down of inventory | $76.0K | ||
| Employee future benefits | $436.0K | $288.0K | |
| Amortization of deferred revenues | -$113.0K | -$856.0K | |
| Change in fair value of warrant and DSU liabilities | -$391.0K | -$2.6M | |
| Other non-cash items | $159.0K | $6.0K | $95.0K |
| Income tax (recovery) expense | $10.0K | $79.0K | -$885.0K |
| Changes in operating assets and liabilities (note 21) | $292.0K | -$2.5M | $58.0K |
| Net cash used in operating activities | -$8.5M | -$14.6M | -$2.6M |
| Exercise of stock options | $13.0K | ||
| Payments on exercise of DSUs | -$42.0K | -$167.0K | |
| Payments on lease liabilities | -$365.0K | -$421.0K | -$370.0K |
| Net cash used in financing activities | -$407.0K | -$588.0K | -$357.0K |
| Cash acquired on acquisition of Aeterna Zentaris Inc. (note 5) | $26.0M | ||
| Purchase of property and equipment | -$706.0K | -$1.2M | -$722.0K |
| Proceeds on disposal of property and equipment | $244.0K | ||
| Changes in restricted cash equivalents | $4.0K | $207.0K | -$8.0K |
| Net cash provided by (used in) investing activities | -$458.0K | $25.1M | -$730.0K |
| Effect of exchange rate changes on cash and cash equivalents | $252.0K | -$212.0K | $157.0K |
| Net change in cash and cash equivalents | -$9.1M | $9.7M | -$3.5M |
Former names
Recent filings
- Jul 6, 20266-K
- Jul 6, 2026SC 13E3/A
- Jul 6, 202615-12G
- Jun 23, 20266-K
- Jun 23, 2026SC 13E3/A
- Jun 18, 2026SC 13E3/A
- Jun 18, 20266-K
- May 20, 20266-K
- May 20, 2026SC 13E3/A
- May 12, 20266-K
- May 12, 20266-K
- May 12, 2026SC 13E3/A
- May 8, 20266-K
- May 8, 2026SC 13E3/A
- May 4, 2026SC 13E3/A
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10